A clinician nudge for referral to a gynecologic oncologist at the time of suspected ovarian cancer diagnosis improved referral rates by 20 percentage points, according to study results.Nearly a third ...

Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease ...

US-based pharmaceutical company AbbVie has reported the final analysis from the Phase III MIRASOL trial, which assessed its ...

Mirvetuximab soravtansine improved overall survival over chemotherapy in patients with FRα-positive, platinum-resistant ovarian cancer.

There are three main types of ovarian cancer: epithelial, germ cell, and stromal. Learn about each type’s defining ...

Vadodara: Doctors at the Manibhai Shivabhai Cancer Centre of Shree Krishna Hospital in Karamsad town of Anand district ...

Cancer is a leading cause of death among women, worldwide..women's day, cancer, women cancer, how to treat women cancer, ...

The operation was successful, leading to the birth of a healthy baby and the removal of the cancerous ovarian masses, she added.Speaking about the patients condition, Gupta said that post-surgery, the ...

A Chorley mum-of-two whose rare and aggressive cancer would have been untreatable 20 years ago is now disease free.

is too expensive for regular funding on the health service as a maintenance therapy for some ovarian cancer patients. In a first draft decision NICE said Lynparza was not cost effective as a ...